COTI-2

N/A

Report date: 2024/11/08 20:00:30
NME

Base Information

Drug NameCOTI-2
Drug Alias NameCOTI-2
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaspase-9 activatorsTubulin modulatorsThymidylate synthase modulators +[7] 
TargetsSerine/threonine-protein kinase AKT2Caspase-9Tubulin +[7] 
Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsFallopian Tube Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCoti
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCotinga Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsFallopian Tube Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A